ENDRA Life Sciences Inc. — Form 8-K
Filed August 17, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 92/100
What the filing says
On June 25, 2026, ENDRA entered into a definitive merger agreement with ASP Isotopes Inc., Noble Africa LLC, and Renergen Limited. Noble Africa will merge with ENDRA's subsidiary and become ENDRA's wholly owned subsidiary; ENDRA will be renamed Noble Africa Inc. A concurrent private placement is expected to generate ~$50 million in gross proceeds, with merger closing anticipated in Q4 2026. ENDRA had $1.7 million cash and $3.8 million restricted cash as of June 30, 2026; Q2 2026 net income was $159,944 (vs. Q2 2025 loss of $1.225 million), primarily driven by $1.6 million in digital asset gains.
Why this rating
Merger fundamentally transforms ENDRA (market cap $2.7M) into helium/gas platform company; ~$50M financing is 1,850% of current market value—existential recapitalization for micro-cap. High execution risk (regulatory, stockholder approval) but represents only viable path forward for cash-depleted biotech.
See more from August 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.